

## National Health Service of England Evaluation of ColoSTAT®

### Highlights

- ✓ The NHS Southern Hub Research Team will evaluate the ColoSTAT® blood-based bowel cancer test for suitability for general use.
- ✓ A full ColoSTAT® system comprising instruments, reagents and software is being transferred to the Hub laboratory in the UK for an independent analytical and clinical evaluation for use within the NHSE environment.
- ✓ This evaluation marks an important next phase towards the international commercialisation of ColoSTAT®

**Melbourne, Australia, 10th December 2025:** Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics technology company is pleased to announce it has entered a collaboration with The Southern Hub Research Team, Royal Surrey NHS Foundation Trust to evaluate the suitability of ColoSTAT® for potential use within the bowel cancer screening pathway in England.

The Company will transfer relevant equipment and reagents to the laboratory in Guildford, England for an independent evaluation of ColoSTAT® in a laboratory with extensive experience in the assessment of bowel cancer screening clinical tests. In the first instance, analytical performance will be independently assessed followed by a further clinical evaluation in patients recruited for the specific purpose.

Independent of this assessment, the Company is in the final stages of the process of completing NATA review in advance of commercialising ColoSTAT® in the domestic market.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via [investors@rhythmbio.com](mailto:investors@rhythmbio.com).

#### About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and X.

#### About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on

**Rhythm Biosciences Ltd**  
ACN 619 459 335  
ASX: RHY

[www.rhythmbio.com](http://www.rhythmbio.com)

**Australian Registered Address**  
Bio21 Molecular Science & Biotechnology Institute  
30 Flemington Road  
Parkville VIC 3010 Australia

T +61 3 8256 2880  
E [info@rhythmbio.com](mailto:info@rhythmbio.com)

#### Directors

Gavin Fox-Smith	Non-Executive Chairman
Sue MacLeman	Non-Executive Director
David Atkins	CEO & Managing Director

research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

**About geneType<sup>™</sup>**

geneType<sup>™</sup> is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit [www.genetype.com](http://www.genetype.com).

For personal use only